MARKET NEWS

VYNE Therapeutics Announces Phase 1b Data for FMX114 From Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Recce Pharmaceuticals Announces Positive Safety Data From Second Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed With RECCE 327
ChemoCentryx Announces EU Approval of TAVNEOS for the Treatment of ANCA-Associated Vasculitis
Petros Pharmaceuticals Launches Two Self-Selection Studies for ED Drug 
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect & Pharmacokinetics Data for BETR-001
Lonza, Forbion, and BioGeneration Ventures Extend Collaboration to Add Development & Manufacturing Services of Small Molecules

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Captisol overcomes solubility and stability hurdles faced during each phase of development. Captisol can make a substance more soluble and an agent more stable. Captisol can convert a solid to a liquid or an oil to an aqueous solution. Combinatorial chemistry, high throughput screening (HTS), and molecular genetics have led to an increase in the number of insoluble and unstable molecules, peptides, and proteins being investigated for their therapeutic activity. There are currently more than 50 Captisol-enabled products in clinical development. This unique technology has enabled several FDA-approved products, including Amgen’s KYPROLIS, Baxter International’s NEXTERONE, Gilead’s VEKLURY, Acrotech Biopharma L.L.C.’s and CASI Pharmaceuticals’ EVOMELA, Melinta Therapeutics’ BAXDELA, and Sage Therapeutics’ ZULRESSO. There are many Captisol-enabled products currently in various stages of development. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248

Kinnate Biopharma Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generation….

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with….

Treadwell Therapeutics Engages Genezen to Advance its T cell Receptor-Based Cell Therapy Pipeline

Treadwell Therapeutics Engages Genezen to Advance its T cell Receptor-Based Cell Therapy Pipeline

Treadwell Therapeutics and Genezen have recently confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients…..

Catalent Launches New Xpress PharmaceuticsT Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials

Catalent Launches New Xpress PharmaceuticsT Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials

Catalent recently announced the launch of its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation….

CordenPharma Collaborates With PeptiSystems on Continuous Peptide Manufacturing & Green Chemistry

CordenPharma Collaborates With PeptiSystems on Continuous Peptide Manufacturing & Green Chemistry

Due to the promising, yet underutilized potential of Green Chemistry and continuous manufacturing synthesis approaches gaining traction in the wider pharmaceutical community, CordenPharma recently announced a collaboration with PeptiSystems, a Swedish-based developer of….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 2 – Analytical Instrumentation
February 9 – Injection Devices